Seres therapeutics reports second quarter 2025 financial results and provides business updates

Following fda input, seres submitted phase 2 study protocol to fda for ser-155 for the prevention of bloodstream infections (bsis) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-hsct) to treat hematological malignancies seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure capital and other resources to enable the clinical advancement of ser-155 and additional live biotherapeutic product candidates seres received the $25 million installment payment, as expected, from nestlÉ health science in july 2025 conference call at 8:30 a.m. et today cambridge, mass.
MCRB Ratings Summary
MCRB Quant Ranking